Drugs / OPN-6602
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06433947 | Aug 2024 → Jul 2026 overdue | plasma cell myeloma | Opna Bio LLC | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPN-6602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433947 ↗ |
| Action | Inhibit | “inhibitor of EP300 and CBP bromodomain” NCT06433947 ↗ |
| Modality | Small molecule | “orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily” NCT06433947 ↗ |
| Route | Oral | “orally active” NCT06433947 ↗ |
| Target | EP300 | “inhibitor of EP300” NCT06433947 ↗ |